ImmunoGen, Inc. (NASDAQ:IMGN) issued its quarterly earnings data on Friday, November 3rd. The biotechnology company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.42), Bloomberg Earnings reports. The firm had revenue of $8.50 million during the quarter, compared to analysts’ expectations of $26.09 million. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the firm posted ($0.51) EPS.
Shares of ImmunoGen (IMGN) traded down $0.45 during trading on Monday, hitting $5.70. 3,755,270 shares of the company’s stock were exchanged, compared to its average volume of 2,894,315. ImmunoGen has a 1-year low of $1.53 and a 1-year high of $8.84. The company has a debt-to-equity ratio of -0.03, a current ratio of 2.81 and a quick ratio of 2.78.
COPYRIGHT VIOLATION NOTICE: “ImmunoGen, Inc. (NASDAQ:IMGN) Posts Earnings Results, Misses Estimates By $0.42 EPS” was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.truebluetribune.com/2017/11/21/immunogen-inc-imgn-announces-quarterly-earnings-results.html.
Several analysts have issued reports on the stock. Canaccord Genuity reaffirmed a “buy” rating and set a $10.00 price target (up previously from $8.00) on shares of ImmunoGen in a research note on Wednesday, August 30th. Cowen and Company reissued a “hold” rating on shares of ImmunoGen in a research note on Tuesday, August 29th. Cantor Fitzgerald reissued a “hold” rating and issued a $5.00 price objective on shares of ImmunoGen in a research note on Monday, September 25th. ValuEngine lowered shares of ImmunoGen from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. Finally, Leerink Swann reaffirmed a “buy” rating on shares of ImmunoGen in a report on Tuesday, August 29th. Two analysts have rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $7.83.
In related news, VP Craig Barrows sold 14,600 shares of the company’s stock in a transaction dated Wednesday, September 13th. The shares were sold at an average price of $6.95, for a total transaction of $101,470.00. Following the completion of the transaction, the vice president now owns 51,100 shares in the company, valued at approximately $355,145. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 6.51% of the company’s stock.
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.